Publications in collaboration with researchers from KU Leuven (25)

2023

  1. Corrigendum: Sorafenib increases cytochrome P450 lipid metabolites in patient with hepatocellular carcinoma (Frontiers in Pharmacology, (2023), 14, (1124214), 10.3389/fphar.2023.1124214)

    Frontiers in Pharmacology

  2. Factors impacting survival after transarterial radioembolization in patients with hepatocellular carcinoma: Results from the prospective CIRT study

    JHEP Reports, Vol. 5, Núm. 2

  3. Impact of body composition in advanced hepatocellular carcinoma: A subanalysis of the SORAMIC trial

    HEPATOLOGY COMMUNICATIONS, Vol. 7, Núm. 6

  4. Non-hypervascular hepatobiliary phase hypointense lesions detected in patients with hepatocellular carcinoma: a post hoc analysis of SORAMIC trial to identify risk factors for progression

    European Radiology, Vol. 33, Núm. 1, pp. 493-500

  5. Predictive Factors for Adverse Event Outcomes After Transarterial Radioembolization with Yttrium-90 Resin Microspheres in Europe: Results from the Prospective Observational CIRT Study

    CardioVascular and Interventional Radiology, Vol. 46, Núm. 7, pp. 852-867

  6. Prognostic role of radiomics-based body composition analysis for the 1-year survival for hepatocellular carcinoma patients

    Journal of Cachexia, Sarcopenia and Muscle, Vol. 14, Núm. 5, pp. 2301-2309

  7. Sorafenib increases cytochrome P450 lipid metabolites in patient with hepatocellular carcinoma

    Frontiers in Pharmacology, Vol. 14

  8. The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 24th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2022

    ESMO Open, Vol. 8, Núm. 3